Cite
The Short-Term Efficacy of Bifidobacterium Quadruple Viable Tablet in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism Rather Than Diversity Regulation.
MLA
Bai, Tao, et al. “The Short-Term Efficacy of Bifidobacterium Quadruple Viable Tablet in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism Rather Than Diversity Regulation.” The American Journal of Gastroenterology, vol. 118, no. 7, July 2023, pp. 1256–67. EBSCOhost, https://doi.org/10.14309/ajg.0000000000002147.
APA
Bai, T., Xu, Z., Xia, P., Feng, Y., Liu, B., Liu, H., Chen, Y., Yan, G., Lv, B., Yan, Z., Dai, N., Long, Y., Wei, W., Shi, Z., Li, X., Fang, X., Gao, H., Qi, L., & Hou, X. (2023). The Short-Term Efficacy of Bifidobacterium Quadruple Viable Tablet in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism Rather Than Diversity Regulation. The American Journal of Gastroenterology, 118(7), 1256–1267. https://doi.org/10.14309/ajg.0000000000002147
Chicago
Bai, Tao, Zhiyue Xu, Peijun Xia, Yichao Feng, Bing Liu, Hongling Liu, Yunwang Chen, et al. 2023. “The Short-Term Efficacy of Bifidobacterium Quadruple Viable Tablet in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism Rather Than Diversity Regulation.” The American Journal of Gastroenterology 118 (7): 1256–67. doi:10.14309/ajg.0000000000002147.